Diagnostic Issues in the Era of Immunotherapy – Pt. 2

What exactly is cancer immunotherapy?
The field of cancer immunotherapy covers multiple therapeutic approaches that may involve stimulation or enhancement of the immune system or blockage of immune inhibitory pathways. Immunotherapeutic modalities may include cancer vaccines, oncolytic viruses, adoptive transfer of ex-vivo activated T-cells and natural killer cells, and the administration of antibodies or recombinant proteins that block immune checkpoint pathways.
This post will focus on the immunotherapy checkpoint inhibitors that target PD-1 or PD-L1,…

Read More

Determining the Tumor Type Is the First Step in Precision Medicine

Advances in genomics and knowledge of tumor biology have uncovered different types of genetic alterations that can predict response to specific molecularly targeted anticancer drugs. These predictive biomarkers may be mutations in individual genes (eg, BRAF V600E), structural rearrangements (eg, EML4-ALK), or copy number variation (eg, HER2 gene amplification). Although these specific genetic alterations are often found in different tumor types, published evidence indicates that biomarker status alone—without tumor type context—does not always predict the efficacy of targeted agents….

Read More

Resolution of Diagnostic Dilemmas in Oncology


Diagnostic uncertainty occurs in 1 in 6 metastatic cancers1-3
Approximately 600,000 patients/year are diagnosed with metastatic cancer.1-3 Of these, ~100,000 display diagnostic uncertainty related to a spectrum of issues.1-3 Some differential diagnoses include lung squamous versus head and neck squamous cell carcinomas, mesothelioma or lung cancer, and subtyping specific neuroendocrine tumors.4,5 Identification of an accurate tumor type diagnosis remains important particularly when clinical presentation is atypical and/or immunohistochemistry (IHC) results do not clearly define a single diagnosis and treatment options can vary widely….

Read More

Welcome to the newly launched CancerTYPE ID® blog!

Thank you for joining us! We’ve launched this blog for healthcare professionals interested in advances in the molecular diagnosis for metastatic cancers. This blog will discuss results from CancerTYPE ID, a molecular classifier that provides a diagnosis of tumor type based on cell lineage. With a single diagnosis, additional information, such as guideline recommended biomarkers, may inform treatment decisions.
“The blog will cover topics related to new information on CancerTYPE ID molecular classification of metastatic cancers that impacts clinical decisions in practice today.”
In addition to discussing ways in which molecular classification may improve clinical decision-making for metastatic cancers,…

Read More

CancerTYPE ID Intended Use and Limitations
CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.